Myriad Will Highlight New Data on Its myRisk(TM) Hereditary Cancer Test at the National Society of Genetic Counselors Annual ...
21 October 2015 - 10:05PM
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular
diagnostics and personalized medicine, today announced that new
data on its myRisk™ Hereditary Cancer molecular diagnostic test
will be featured in five presentations at the National Society of
Genetic Counselors (NSGC) Annual Conference being held Oct. 21 to
24, 2015 in Pittsburgh, Pa.
"Myriad is a pioneer in translating genetic information into
products that save and improve lives. More than ever, we're
dedicated to research that advances the science of hereditary
cancer testing for patients now and in the future," said Johnathan
Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic
Laboratories. "The data we're presenting at NSGC this year
demonstrate that the myRisk Hereditary Cancer Panel identifies more
harmful mutations than testing one gene at a time.
Furthermore, as we expand our testing to broader gene panels and
identify mutations in genes that have not traditionally been linked
to certain family histories, we are challenging the fundamentals of
our historical thinking on cancer genetics."
A list of Myriad's presentations at NSGC (#NSGC2015)
follows:
Poster Presentations
- Title: Pathogenic mutations identified in patients with 6 or
more colon polyps.
Date: Thursday, Oct. 22, 2015, 2:00-3:00 p.m. ET.
Location: Poster 55.
- Title: Hereditary Cancer Testing in Patients of Ashkenazi
Jewish Ancestry in the Era of Panel Testing.
Date: Thursday, Oct. 22, 2015, 2:00-3:00 p.m. ET.
Location: Poster 71
- Title: Pedigree modeling demonstrates that family history
performs poorly for the identification of women with inherited
risks for breast cancer.
Date: Thursday, Oct. 22, 2015, 2:00-3:00 p.m. ET.
Location: Poster 111.
- Title: Outcomes of multi-gene testing for inherited cancer risk
in patients of varied ancestries.
Date: Friday, Oct. 23, 2015, 1:15-2:15 p.m. ET.
Location: Poster 72.
- Title: Identification of a Recurrent Pathogenic Variant in
BRIP1.
Date: Friday, Oct. 23, 2015, 1:15-2:15 p.m. ET.
Location: Poster 74.
For more information about these presentations, including a
complete list of posters, please visit the NSGC website at
http://nsgc.org/2015aec.
About Myriad myRisk™ Hereditary Cancer
Testing
The Myriad myRisk Hereditary Cancer test uses next-generation
sequencing technology to evaluate 25 clinically significant genes
associated with eight hereditary cancer sites including: breast,
colon, ovarian, endometrial, pancreatic, prostate and gastric
cancers and melanoma. For more information visit:
https://www.myriad.com/products-services/hereditary-cancers/myrisk-hereditary-cancer/.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company
dedicated to being a trusted advisor transforming patient lives
worldwide with pioneering molecular diagnostics. Myriad
discovers and commercializes molecular diagnostic tests that:
determine the risk of developing disease, accurately diagnose
disease, assess the risk of disease progression, and guide
treatment decisions across six major medical specialties where
molecular diagnostics can significantly improve patient care and
lower healthcare costs. Myriad is focused on three strategic
imperatives: transitioning and expanding its hereditary cancer
testing markets, diversifying its product portfolio through the
introduction of new products and increasing the revenue
contribution from international markets. For more information
on how Myriad is making a difference, please visit the Company's
website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan,
BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and
Prolaris are trademarks or registered trademarks of Myriad
Genetics, Inc. or its wholly owned subsidiaries in the United
States and foreign countries. MYGN-F, MYGN-G
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements related to presenting new data at NSGC,
which demonstrate that the myRisk Hereditary Cancer Panel
identifies more harmful mutations than testing one gene at a time;
translating genetic information into products that save and
improve lives; advancing the science of hereditary cancer
testing for patients now and in the future; our ability to
challenge the fundamentals of our historical thinking on cancer
genetics; and the Company's strategic directives under the caption
"About Myriad Genetics." These "forward-looking statements"
are based on management's current expectations of future events and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by forward-looking statements. These risks and
uncertainties include, but are not limited to: the risk that sales
and profit margins of our molecular diagnostic tests and
pharmaceutical and clinical services may decline; risks related to
our ability to transition from our existing product portfolio to
our new tests, including unexpected costs and delays; risks related
to decisions or changes in governmental or private insurers'
reimbursement levels for our tests or our ability to obtain
reimbursement for our new tests at comparable levels to our
existing tests; risks related to increased competition and the
development of new competing tests and services; the risk that we
may be unable to develop or achieve commercial success for
additional molecular diagnostic tests and pharmaceutical and
clinical services in a timely manner, or at all; the risk that we
may not successfully develop new markets for our molecular
diagnostic tests and pharmaceutical and clinical services,
including our ability to successfully generate revenue outside the
United States; the risk that licenses to the technology underlying
our molecular diagnostic tests and pharmaceutical and clinical
services and any future tests and services are terminated or cannot
be maintained on satisfactory terms; risks related to delays or
other problems with operating our laboratory testing facilities and
our healthcare clinic; risks related to public concern over genetic
testing in general or our tests in particular; risks related to
regulatory requirements or enforcement in the United States and
foreign countries and changes in the structure of the healthcare
system or healthcare payment systems; risks related to our ability
to obtain new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire; risks related to our projections about our business,
results of operations and financial condition; risks related to the
potential market opportunity for our products and services; the
risk that we or our licensors may be unable to protect or that
third parties will infringe the proprietary technologies underlying
our tests; the risk of patent-infringement claims or challenges to
the validity of our patents or other intellectual property; risks
related to changes in intellectual property laws covering our
molecular diagnostic tests and pharmaceutical and clinical services
and patents or enforcement in the United States and foreign
countries, such as the Supreme Court decision in the lawsuit
brought against us by the Association for Molecular Pathology et
al; risks of new, changing and competitive technologies and
regulations in the United States and internationally; and other
factors discussed under the heading "Risk Factors" contained in
Item 1A of our most recent Annual Report on Form 10-K for the
fiscal year ended June 30, 2015, which has been filed with the
Securities and Exchange Commission, as well as any updates to those
risk factors filed from time to time in our Quarterly Reports on
Form 10-Q or Current Reports on Form 8-K. All information in
this press release is as of the date of the release, and Myriad
undertakes no duty to update this information unless required by
law.
CONTACT: Media Contact:
Ron Rogers
(908) 285-0248
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2024 to May 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2023 to May 2024